Celldex Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2013-12-31 was $181.56M, a 218650.60% increase year-over-year.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2013-09-30 was $0.00.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2013-06-30 was $0.00.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2013-03-31 was $97.00M, a 123.50% increase year-over-year.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $432.30M, a 99.93% increase from fiscal 2023.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $216.22M.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $269.89M, a 90.92% increase from fiscal 2020.
- Celldex Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $141.36M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $432.30M 10-K · filed 2025-02-27 | |
| 2023-12-31 | $216.22M 10-K · filed 2024-02-26 | |
| 2021-12-31 | $269.89M 10-K · filed 2024-02-26 | |
| 2020-12-31 | $141.36M 10-K · filed 2023-02-28 | |
| 2015-12-31 | $188.84M 10-K · filed 2018-03-07 | |
| 2013-12-31 | $181.56M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-02-25 | $278.56M 10-K/A · filed 2016-02-25 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $97.08M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $97.08M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $97.00M 10-Q · filed 2014-05-01 | $97.08M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $43.48M 10-K · filed 2015-02-24 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | |
| 2012-03-31 | $43.40M 10-Q · filed 2013-05-03 | |
| 2011-12-31 | $33.70M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |